JP2013533253A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533253A5
JP2013533253A5 JP2013518241A JP2013518241A JP2013533253A5 JP 2013533253 A5 JP2013533253 A5 JP 2013533253A5 JP 2013518241 A JP2013518241 A JP 2013518241A JP 2013518241 A JP2013518241 A JP 2013518241A JP 2013533253 A5 JP2013533253 A5 JP 2013533253A5
Authority
JP
Japan
Prior art keywords
carbon atoms
enantiomer
atoms
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518241A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533253A (ja
JP5881692B2 (ja
Filing date
Publication date
Priority claimed from US12/827,505 external-priority patent/US9610274B2/en
Application filed filed Critical
Publication of JP2013533253A publication Critical patent/JP2013533253A/ja
Publication of JP2013533253A5 publication Critical patent/JP2013533253A5/ja
Application granted granted Critical
Publication of JP5881692B2 publication Critical patent/JP5881692B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518241A 2010-06-30 2011-06-27 双極性障害を治療する方法 Active JP5881692B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/827,505 2010-06-30
US12/827,505 US9610274B2 (en) 2010-06-30 2010-06-30 Methods for treating bipolar disorder
PCT/KR2011/004676 WO2012002687A2 (en) 2010-06-30 2011-06-27 Methods for treating bipolar disorder

Publications (3)

Publication Number Publication Date
JP2013533253A JP2013533253A (ja) 2013-08-22
JP2013533253A5 true JP2013533253A5 (enExample) 2014-08-07
JP5881692B2 JP5881692B2 (ja) 2016-03-09

Family

ID=45400168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518241A Active JP5881692B2 (ja) 2010-06-30 2011-06-27 双極性障害を治療する方法

Country Status (13)

Country Link
US (2) US9610274B2 (enExample)
EP (1) EP2590645B1 (enExample)
JP (1) JP5881692B2 (enExample)
KR (1) KR101828934B1 (enExample)
CN (1) CN102985085B (enExample)
AU (1) AU2011272156B2 (enExample)
BR (1) BR112012033738A2 (enExample)
CA (1) CA2801241C (enExample)
ES (1) ES2654615T3 (enExample)
MX (2) MX2012014686A (enExample)
PL (1) PL2590645T3 (enExample)
RU (1) RU2653408C2 (enExample)
WO (1) WO2012002687A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006254899B2 (en) 2005-06-08 2011-11-24 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
RU2567801C2 (ru) 2009-06-22 2015-11-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения и профилактики усталости
US9359290B2 (en) 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
PL3021838T3 (pl) * 2013-07-18 2021-03-08 Jazz Pharmaceuticals Ireland Limited Leczenie otyłości
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CN120574152A (zh) 2016-09-06 2025-09-02 爱尔兰贾兹制药有限公司 (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的溶剂化物形式的晶体、其制备方法、组合物及用途
MY202185A (en) 2016-10-06 2024-04-15 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol compounds and uses therof
JP7208139B2 (ja) * 2016-12-14 2023-01-18 エスケー バイオファーマスティカルズ カンパニー リミテッド 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用
EP3630072A4 (en) 2017-06-02 2021-03-10 Jazz Pharmaceuticals Ireland Limited METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness
MX2020001146A (es) 2017-07-31 2020-08-20 Jazz Pharmaceuticals Ireland Ltd Analogos de carbamoil fenilalaninol y usos de los mismos.
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
DE69618663T2 (de) 1996-10-10 2002-08-14 Sk Corp., Seoul/Soul O-carbamoyl-phenylalaninol-zusammensetzungen und ihre pharmazeutisch anwendbaren salzen
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US6294555B1 (en) 1998-04-28 2001-09-25 Dainippon Pharmaceutical Co., Ltd. 1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivative, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
AU3113902A (en) 2000-12-21 2002-07-01 Bristol Myers Squibb Co Thiazolyl inhibitors of tec family tyrosine kinases
US6815464B2 (en) 2001-02-27 2004-11-09 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in the treatment of pain
DE60221670T2 (de) 2001-02-27 2008-04-30 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
US7259157B2 (en) 2001-04-03 2007-08-21 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
US20040204341A1 (en) 2001-06-12 2004-10-14 Christopher Allen Nr2b receptor antagonists for the treatment or prevention of migraines
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
JP2006502180A (ja) 2002-09-20 2006-01-19 ファイザー株式会社 5−ht4レセプターモジュレーターとしてのn−置換されたピペリジニル−イミダゾピリジン化合物
WO2004094418A1 (en) 2003-04-21 2004-11-04 Pfizer Inc. Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
CA2537127C (en) 2003-09-03 2011-04-05 Pfizer Inc. Benzimidazolone compounds having 5-ht4 receptor agonistic activity
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
KR20070083826A (ko) 2004-10-28 2007-08-24 에스케이 주식회사 우울증을 위한 부가 요법
KR100969402B1 (ko) 2005-04-08 2010-07-14 화이자 프로덕츠 인크. I형 글리신 수송 억제제로서의 비시클릭 [3.1.0]헤테로아릴 아미드
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
AU2006254899B2 (en) * 2005-06-08 2011-11-24 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
DE602006012670D1 (de) 2005-06-22 2010-04-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
CA2616721C (en) 2005-07-26 2014-01-21 Janssen Pharmaceutica N.V. Methods for treating substance-related disorders
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
CA2673487A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions
HUP0700370A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
RU2567801C2 (ru) 2009-06-22 2015-11-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения и профилактики усталости
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101097605B1 (ko) 2009-11-04 2011-12-22 알.에프 에이치아이씨 주식회사 도허티 증폭기
WO2011055944A2 (en) 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Methods for treating fibromyalgia syndrome
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(adhd)의 치료 방법
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome

Similar Documents

Publication Publication Date Title
JP2013531008A5 (enExample)
RU2012155118A (ru) Способы лечения биполярного расстройства
RU2012123154A (ru) Способы лечения синдрома фибромиалгии
JP2015505296A5 (enExample)
JP2013510120A5 (enExample)
JP2011504903A5 (enExample)
RU2015143610A (ru) Лечение катаплексии
JP2013536188A5 (enExample)
JP2015516420A5 (enExample)
JP2013537203A5 (enExample)
JP2011517453A5 (enExample)
JP2014051526A5 (enExample)
JP2013538802A5 (enExample)
EA201071173A1 (ru) Применение частиц твёрдого носителя для улучшения технологических характеристик фармацевтического агента
JP2013509392A5 (enExample)
JP2017533968A5 (enExample)
JP2014511892A5 (enExample)
RU2014149183A (ru) Проницаемые ингибиторы гликозидазы и их применения
JP2011513410A5 (enExample)
JP2012530779A5 (enExample)
RU2010126056A (ru) Органические соединения
RU2013140169A (ru) Противоопухолевое терапевтическое средство
JP2010522710A5 (enExample)
MX2014004144A (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
PH12013501895A1 (en) Ethynyl derivatives as positive allosteric modulators of the mglur5